NANTES, FRANCE--(Marketwire - April 08, 2009) -
| Highlighted Links |
|
PARTICIPATION IN SMALLCAP EVENT 27 & 28 APRIL 2009 IN PARIS
Nantes (France) - 8 April 2009
VIVALIS (NYSE Euronext Paris: VLS), a biopharmaceutical company that provides the pharmaceutical industry innovative cell-based solutions for the manufacture of vaccines and proteins and develops drugs to prevent and treat viral diseases, will participate in the Smallcap Event to be held in Paris on 27 and 28 April 2009 (Hôtel Pullman Tour Eiffel, 18 avenue de Suffren).
VIVALIS will present its technological and commercial advances of 2008, financial results including notably positive net income for the period and its strategic outlook.
VIVALIS’ presence at this forum reflects its commitment to develop strong relations with investors and raise its visibility within the financial community. The Smallcap Event will also provide an opportunity for fund managers to meet Franck Grimaud, VIVALIS’ CEO, to learn more about the company, its market and strategic outlook.
*******************
Financial press release:
29 April 2009, after NYSE Euronext market closing: 2009 first-quarter sales
About VIVALIS (www.vivalis.com)
VIVALIS (NYSE - Euronext: VLS) is a biopharmaceutical company that provides the pharmaceutical industry innovative cell-based solutions for the manufacture of vaccines and proteins, and develops drugs to prevent and treat viral diseases. VIVALIS’ know-how and proprietary technologies are commercially exploited in three main areas:
1. The development and manufacturing of vaccines. VIVALIS offers research and commercial licenses for its EB66® cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of viral vaccines. VIVALIS receives upfront fees, milestone payments and royalties on its licensees’ net sales.
2. The development of production systems for recombinant proteins and monoclonal antibodies. VIVALIS licenses to pharmaceutical and biotechnology companies its EB66® cell line for the production of recombinant proteins. VIVALIS receives upfront fees, milestone payments and royalties on its licensees’ net sales.
3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (Hepatitis C).
Based in Nantes (France), VIVALIS was created in 1999 by Group Grimaud (1,450 employees), the n degrees2 group worldwide in animal genetic breeding. VIVALIS has established more than 30 partnerships with worldwide leaders in the sector. VIVALIS is a member of the French Atlantic Biotherapies cluster.
+-------------------------+-+ |VIVALIS | | +-------------------------+-+ |Listed on Euronext Paris | | |– Compartment C of NYSE | | |Euronext | | +-------------------------+-+ |Reuters: VLS.PA – | | |Bloomberg: VLS FP | | +-------------------------+-+ |Member of NYSE Euronext’s| | |Next Biotech index | | +-------------------------+-+ +-------------------------+-+
Investor Relations:
VIVALIS
Franck Grimaud, CEO
Email: investors@vivalis.com
NewCap
Financial communication Agency
Steve Grobet / Emmanuel Huynh
Tel.: +33 (0) 1 44 71 94 91
Email: vivalis@newcap.fr
This information is provided by HUGIN
